Patents by Inventor Jean Pierre Etchegaray
Jean Pierre Etchegaray has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20160106764Abstract: The present invention is directed to a pharmaceutical composition in unit dose form for orally delivering doxycycline to a human, the pharmaceutical composition comprising: a capsule, wherein the capsule is coated with a delayed release layer; wherein the delayed release layer comprises about 4 to 6 mg of doxycycline monohydrate and a binding agent, and wherein the delayed release layer is coated with an enteric coating; wherein the enteric coating dissolves at pH of about 5 to 6, and wherein the enteric coating is coated with an immediate release layer; wherein the immediate release layer comprises about 32 mg of doxycycline monohydrate and a binding agent, wherein the relative mean Cmax of the pharmaceutical composition is within 80.00% to 125.00% of a Cmax value of 510±220.7 ng/mL, after administration of a single dose of the pharmaceutical composition to humans in a fasting state; and wherein the relative mean AUC(0-?) of the pharmaceutical composition is within 80.00% to 125.Type: ApplicationFiled: December 29, 2015Publication date: April 21, 2016Inventors: Jean-Pierre Etchegaray, Nathalie Wagner, Manish S. Shah, Ray J. Difalco
-
Publication number: 20150245998Abstract: The present invention is directed to a pharmaceutical composition in unit dose form for orally delivering doxycycline to a human, the pharmaceutical composition comprising: a capsule, wherein the capsule is coated with a delayed release layer; wherein the delayed release layer comprises about 4 to 6 mg of doxycycline monohydrate and a binding agent, and wherein the delayed release layer is coated with an enteric coating; wherein the enteric coating dissolves at pH of about 5 to 6, and wherein the enteric coating is coated with an immediate release layer; wherein the immediate release layer comprises about 32 mg of doxycycline monohydrate and a binding agent, wherein the relative mean Cmax of the pharmaceutical composition is within 80.00% to 125.00% of a Cmax value of 510±220.7 ng/mL, after administration of a single dose of the pharmaceutical composition to humans in a fasting state; and wherein the relative mean AUC(0-?) of the pharmaceutical composition is within 80.00% to 125.Type: ApplicationFiled: May 13, 2015Publication date: September 3, 2015Inventors: Jean-Pierre Etchegaray, Nathalie Wagner, Manish S. Shah, Ray J. Difalco
-
Publication number: 20140309198Abstract: An improved method for treating acne is described. The method involves 16-week, once daily, oral administration of about 40 mg doxycycline in a pharmaceutical composition containing about 30 mg doxycycline in an immediate release portion and about 10 mg doxycycline in a delayed release portion. It was surprisingly discovered that the 16-week, once daily, oral administration of about 40 mg doxycycline has achieved same or superior efficacy than that of 100 mg doxycycline, but with a significant reduction in adverse events.Type: ApplicationFiled: April 4, 2014Publication date: October 16, 2014Inventors: Vasant Kumar MANNA, Sandrine SEGURA, Ludovic BUSSARD, Jean-Pierre ETCHEGARAY, Philip FREIDENREICH
-
Publication number: 20140271834Abstract: The present invention is directed to a pharmaceutical composition in unit dose form for orally delivering doxycycline to a human, the pharmaceutical composition comprising: a capsule, wherein the capsule is coated with a delayed release layer; wherein the delayed release layer comprises about 4 to 6 mg of doxycycline monohydrate and a binding agent, and wherein the delayed release layer is coated with an enteric coating; wherein the enteric coating dissolves at pH of about 5 to 6, and wherein the enteric coating is coated with an immediate release layer; wherein the immediate release layer comprises about 32 mg of doxycycline monohydrate and a binding agent, wherein the relative mean Cmax of the pharmaceutical composition is within 80.00% to 125.00% of a Cmax value of 510±220.7 ng/mL, after administration of a single dose of the pharmaceutical composition to humans in a fasting state; and wherein the relative mean AUC(0-?) of the pharmaceutical composition is within 80.00% to 125.Type: ApplicationFiled: October 16, 2013Publication date: September 18, 2014Applicants: Cerovene, Inc., Galderma S.A.Inventors: Jean-Pierre Etchegaray, Nathalie Wagner, Manish S. Shah, Ray J. Difalco
-
Publication number: 20140199469Abstract: A method for producing a sustained-release tablet having improved stability and content uniformity is provided. The method involves first preparing a core tablet by granulating, drying, milling, blending, and compressing a mixture of active and inactive ingredients. Four coating layers are applied to the core tablet: an inner layer, an enteric coating layer, an active layer, and an outer layer. The active ingredient may be a tetracycline, such as doxycycline. A sustained-release tablet prepared according to the method is also described.Type: ApplicationFiled: February 25, 2014Publication date: July 17, 2014Applicant: Galderma S.A.Inventors: Sandrine SEGURA, Ludovic BUSSARD, Jean-Pierre ETCHEGARAY
-
Patent number: 8652516Abstract: The present invention is directed to a pharmaceutical composition in unit dose form for orally delivering doxycycline to a human, the pharmaceutical composition comprising: a capsule, wherein the capsule is coated with a delayed release layer; wherein the delayed release layer comprises about 4 to 6 mg of doxycycline monohydrate and a binding agent, and wherein the delayed release layer is coated with an enteric coating; wherein the enteric coating dissolves at pH of about 5 to 6, and wherein the enteric coating is coated with an immediate release layer; wherein the immediate release layer comprises about 32 mg of doxycycline monohydrate and a binding agent, wherein the relative mean Cmax of the pharmaceutical composition is within 80.00% to 125.00% of a Cmax value of 510±220.7 ng/mL, after administration of a single dose of the pharmaceutical composition to humans in a fasting state; and wherein the relative mean AUC(0-?) of the pharmaceutical composition is within 80.00% to 125.Type: GrantFiled: June 27, 2013Date of Patent: February 18, 2014Assignees: Cerovene, Inc., Galderma S.A.Inventors: Jean-Pierre Etchegaray, Nathalie Wagner, Manish S. Shah, Ray J. Difalco
-
Publication number: 20130196954Abstract: An improved method for treating acne is described. The method involves 16-week, once daily, oral administration of about 40 mg doxycycline in a pharmaceutical composition containing about 30 mg doxycycline in an immediate release portion and about 10 mg doxycycline in a delayed release portion. It was surprisingly discovered that the 16-week, once daily, oral administration of about 40 mg doxycycline has achieved same or superior efficacy than that of 100 mg doxycycline, but with a significant reduction in adverse events.Type: ApplicationFiled: March 13, 2013Publication date: August 1, 2013Inventors: Vasant Kumar MANNA, Sandrine SEGURA, Ludovic BUSSARD, Jean-Pierre ETCHEGARAY, Phil FREIDENREICH
-
Publication number: 20120100214Abstract: A method for producing a sustained-release tablet having improved stability and content uniformity is provided. The method involves first preparing a core tablet by granulating, drying, milling, blending, and compressing a mixture of active and inactive ingredients. Four coating layers are applied to the core tablet: an inner layer, an enteric coating layer, an active layer, and an outer layer. The active ingredient may be a tetracycline, such as doxycycline. A sustained-release tablet prepared according to the method is also described.Type: ApplicationFiled: October 21, 2011Publication date: April 26, 2012Applicant: Galderma S.A.Inventors: Sandrine SEGURA, Ludovic BUSSARD, Jean-Pierre ETCHEGARAY
-
Patent number: 7429654Abstract: Regulatory elements of the 5?UTR of cold-shock inducible genes that prolong the expression of cold-shock inducible genes under conditions that elicit the cold-shock response in a bacterium, repress the expression of the cold-shock inducible genes under physiological conditions, or enhance the translation of cold-shock inducible genes under conditions that elicit a cold-shock response in bacteria; vectors incorporating these elements; and methods for expressing proteins.Type: GrantFiled: April 19, 2000Date of Patent: September 30, 2008Assignee: University of Medicine and Dentistry of New JerseyInventors: Li Fang, Weining Jiang, Masanori Mitta, Masayori Inouye, Jean-Pierre Etchegaray, Kunitoshi Yamanaka
-
Patent number: 6962713Abstract: In particular this invention provides for spot-on compositions for the treatment or prophylaxis of parasite infestations in mammals or birds which comprise: (1) a composition comprising (A) an effective amount of a 1-phenylpyrazole derivative; and/or (B) an effective amount of a macrocyclic lactone antihelmintic or antiparasitic agent; (2) an acceptable liquid carrier vehicle; and (3) optionally, a crystallization inhibitor. The invention also provides for a method of treating parasitic infestations or for the prophylaxis of parasite infestations in mammals or birds which comprises topically applying to said mammal treating parasitic infestations or for the prophylaxis of parasite infestations in mammals or birds which comprises topically applying to said mammal or bird an effective amount of a composition according to the present invention.Type: GrantFiled: May 24, 2002Date of Patent: November 8, 2005Assignee: MerialInventors: Anne-Marie Huet, Bruno Julia, Jean-Pierre Etchegaray, André Weil, Philippe Jeannin
-
Patent number: 6867229Abstract: Composition which is useful in particular for the treatment and protection of domestic animals which are infested with parasites or are likely to be infested with them, these compositions comprising, in the form of a ready-to-use solution: a) an insecticidal active substance of formula (I), b) a crystallization inhibitor, c) an organic solvent having a dielectric constant of between 10 and 35, preferably of between 20 and 30, d) an organic co-solvent having a boiling point below 100° C., preferably below 80° C., and a dielectric constant of between 10 and 40, preferably of between 20 and 30.Type: GrantFiled: April 8, 2002Date of Patent: March 15, 2005Assignee: MerialInventor: Jean Pierre Etchegaray
-
Patent number: 6797724Abstract: A spot-on composition for the treatment or protection of a domestic animal against parasitic infestation comprising, (a) an insecticidal active substance of the formula (X): (b) an organic solvent; and (c) a vehicle; and (d) an emollient; wherein the composition comprises from 0.05 to 25% weight/volume of the compound of formula (X), and the compound of formula (X) is applied in a dose between 0.1 and 2 mg/kg animal weight.Type: GrantFiled: April 11, 2002Date of Patent: September 28, 2004Assignee: MerialInventors: Jean-Pierre Etchegaray, Philippe Jeannin
-
Patent number: 6716442Abstract: Method for eradicating fleas in domestic or accommodation premises of a domestic or laboratory mammal is provided. The method involves topically applying, at least monthly, to the domestic or laboratory mammal, a parasitically effective amount of compound of Formula I.Type: GrantFiled: December 27, 1999Date of Patent: April 6, 2004Assignee: MerialInventors: James S. Hunter, Jean-Pierre Etchegaray, Bruno Julia, Philippe Jeannin
-
Publication number: 20030050327Abstract: In particular this invention provides for spot-on compositions for the treatment or prophylaxis of parasite infestations in mammals or birds which comprise:Type: ApplicationFiled: May 24, 2002Publication date: March 13, 2003Inventors: Anne-Marie Huet, Bruno Julia, Jean-Pierre Etchegaray, Andre Weil, Philippe Jeannin
-
Publication number: 20030007989Abstract: Disclosed is a process for using a compound according to formula (I) or formula (II) to prepare a mixture for the eradication of ticks in the living quarters of small mammals, especially cats and dogs. Said process consists in applying as needed to the animal or animals of the habitat concerned a topical formulation in sufficiently pesticidal quantities of a compound according to formula (I), or possibly formula (II), at monthly intervals.Type: ApplicationFiled: December 27, 1999Publication date: January 9, 2003Inventors: JAMES S. HUNTER, JEAN-PIERRE ETCHEGARAY, BRUNO JULIA, PHILIPPE JEANNIN
-
Patent number: 6482425Abstract: The invention concerns a method and a composition against parasites and particularly ectoparasites and, preferably also endoparasites of small mammals and in particular dogs and cats. The composition contains a compound (A) of formula (I) and a compound (B) consisting of an endectoparasiticide of the macrocylic lactone type.Type: GrantFiled: March 17, 1999Date of Patent: November 19, 2002Assignee: MerialInventors: Anne-Marie Huet, Bruno Julia, Jean-Pierre Etchegaray, André Weil, Philippe Jeannin
-
Publication number: 20020155147Abstract: The direct pour-on skin solution intended to eliminate parasites, in particular Boophilus microplus, from cattle and sheep comprises from 0.05 to 25%, preferably from 0.05 to 10%, and in particular from 0.Type: ApplicationFiled: April 11, 2002Publication date: October 24, 2002Inventors: Jean-Pierre Etchegaray, Philippe Jeannin
-
Publication number: 20020151577Abstract: Composition which is useful in particular for the treatment and protection of domestic animals which are infested with parasites or are likely to be infested with them, these compositions comprising, in the form of a ready-to-use solution:Type: ApplicationFiled: April 8, 2002Publication date: October 17, 2002Inventor: Jean Pierre Etchegaray
-
Patent number: 6426333Abstract: In particular this invention provides for spot-on compositions for the treatment or prophylaxis of parasite infestations in mammals or birds which comprise: (1) a composition comprising (A) an effective amount of a 1-phenylpyrazole derivative; and/or (B) an effective amount of a macrocyclic lactone antihelmintic or antiparasitic agent; (2) an acceptable liquid carrier vehicle; and (3) optionally, a crystallization inhibitor. The invention also provides for a method of treating parasitic infestations or for the prophylaxis of parasite infestations in mammals or birds which comprises topically applying to said mammal treating parasitic infestations or for the prophylaxis of parasite infestations in mammals or birds which comprises topically applying to said mammal or bird an effective amount of a composition according to the present invention.Type: GrantFiled: August 17, 1999Date of Patent: July 30, 2002Assignee: MerialInventors: Anne-Marie Huet, Bruno Julia, Jean-Pierre Etchegaray, André Weil, Philippe Jeannin
-
Patent number: 6413542Abstract: The direct pour-on skin solution intended to eliminate parasites, in particular Boophilus microplus, from cattle and sheep comprises from 0.05 to 25%, preferably from 0.05 to 10%, and in particular from 0.1 to 2% weight/volume, relative to the total solution, of a compound of formula (I): in a formulation at low volume, designed to release the compound (I) onto the skin and the hairs for a contact action against parasites.Type: GrantFiled: November 29, 1999Date of Patent: July 2, 2002Assignee: MerialInventors: Jean-Pierre Etchegaray, Philippe Jeannin